ARV-766 is identified as an orally available and potent PROTAC that targets the degradation of both the wild-type androgen receptor (AR) and key AR LBD mutants, specifically the prevalent AR L702H, H875Y, and T878A mutations[1].
上海安毕达生物科技有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
邵经理